Biotech company Moderna said it expects to make almost $20 billion this year from sales of its COVID-19 vaccine-- the only product that it has on the market. $STAB
“Submitting this study protocol to the FDA is a critical milestone in the development of our COVID-19 program,” said Michael K. Handley, President and Chief Executive Officer, Statera Biopharma. “As the world continues to struggle with the COVID-19 pandemic, post-acute COVID syndrome remains a widespread, often debilitating condition that is not well understood. With STAT-205 Statera looks to potentially offer a promising treatment approach to those patients facing the long-lasting burden of the illness.” $STAB